Product Sheets and Technology Offers

AquaNANO - Nanoprobes Based Fast Drinking Water Analysis

© Fraunhofer IME | Florian Schröper

Drinking water is our most important foodstuff and is therefore subject to strict and frequent controls. Nevertheless, there are always situations in which contamination with pathogens cannot be ruled out, e.g. after floods or earthquakes. In addition, bioterrorist attack scenarios cannot be ruled out, as supply facilities represent a potential target because of their nationwide infrastructure and central feed-in points. Established analyses are laboratory-based, complex and time-consuming. There is currently a lack of reliable and sensitive rapid test methods that can be used on site. The aim of the joint AquaNANO project is to develop a novel mobile analysis system that can detect impurities in drinking water in the shortest possible time.

Innovative Detection Technologies and Assay Designs

© Fraunhofer IME | Florian Schröper

Fraunhofer IME is an application-oriented research institute focusing on the development of innovative analysis platforms. In close cooperation with partners from science and industry, we develop tailor-made solutions for specific challenges. One of the research focuses of Fraunhofer IME is the development of tailor-made immunological assays and the production of specific antibodies for these purposes. In addition to adapting classical methods such as the enzyme coupled immunosorbent assay (ELISA) to specific problems, we also focus on the development of innovative rapid test platforms, e.g. using special magnetic nanoprobes.

Magn-I-tekt Magnetic Immunodetection for Mobile and Rapid IdentifIcation of Plant Pathogens

© Fraunhofer IME | Florian Schröper

Plant pathogens such as viruses and fungi have a strong global impact on crop plants and lead to considerable economic losses of up to 30 percent. The early identification and quantification of plant pathogens is of crucial importance in order to initiate appropriate measures in good time, such as the use of plant protection products, and thus prevent the spread of such diseases. Routine testing of random plant samples for the presence of certain pathogens is a suitable strategy. For this purpose, we have developed a novel rapid test method using antibody-functionalized magnetic particles. Continuous sampling in the field in combination with the mobile rapid test allows early detection of pathogenic infestations and efficient control of the amount of pesticide.

DNA-Sequencing

© Fraunhofer IME | Birgit Orthen

DNA sequencing is a very labor-intensive and time-consuming process that has become indispensable in modern biological research. It is required to characterize new genes or to verify the identity of recombinant DNA. To support our customers in their research activities, we offer a portfolio of DNA sequencing and related services:
- Plasmid DNA Preparation
- PCR Product Purification
- Preparation of sequence reactions
- Analysis of sequence reactions

Antibody Technologies

© Fraunhofer IME | Anne Peuscher

At Fraunhofer IME, murine antibodies have been produced using hybridoma technology for many years. Based on this, our expertise has expanded into other areas of antibody work. A modern cell culture laboratory with automated cell cultivation is available for the generation and selection of antibody producing cells. The purification of the produced antibodies as well as characterization and functional analysis (e.g. by gel electrophoresis, ELISA and Surface Plasmon Resonance) are routinely performed. The cloning of the genetic information of the antibodies and their further optimization as well as the conversion into other antibody formats e.g. single chain antibodies (scFv) are an integral part of our work.

Biocore Interaction Analysis

© Fraunhofer IME | Holger Spiegel

The activity of active pharmaceutical ingredients is usually based on a molecular interaction of the respective active substance with specific receptor or target molecules in the patient's body. The reliable and detailed quantitative characterization of biomolecules in terms of interaction parameters such as specificity, binding strength and stoichiometry plays a decisive role in the identification and development of new drugs and vaccines as well as in quality control in the manufacture of new drugs and vaccines.

Chronic Testing of Lothic Invertebrate Species

© Fraunhofer IME | Klaus Peter Kappest


Species Sensitivity Distributions (SSDs) are increasingly used in ecological risk assessment of chemicals. SSDs compile toxicity data for a set of species tests to estimate hazardous concentrations (HCx), which represent a specific proportion of species in a communitythat would be affected. For the risk assessment of plant protection products tests for at least eight invertebrate species of the sensitive taxonomic group are required for the SSD approach. Until now, most invertebrate SSDs for plant protection products are based on acute test data because to conduct for example chronic tests with eight different aquatic arthropoda species is difficult. The Fraunhofer IME is able to perform chronic testing of different invertebrate species which could provide toxicity data for the SSD approach.

Nuclear Magnetic Resonance (NMR) Spectroscopy

© Fraunhofer IME | Studio 95

All organic compounds undergo transformation and degradation processes that generate new substances with completely different properties. Before products can be registered, it is therefore necessary to understand how they are metabolized and degraded in different environmental matrices. Regulatory approval procedures for this are challenging because highly-sensitive analytical methods are needed to detect and identify the minute quantities of transformation products generated by metabolism and environmental degradation. Nuclear magnetic resonance (NMR) spectroscopy is the most efficient analytical method for determining the structure of organic substances.The NMR suite is supported by a high-resolution OrbitrapTM Hybrid FT mass spectrometer that can determine the chemical formulae of unknown substances to complement the structural data.

Combination Therapy of Type 1 Diabetes

© Fraunhofer IME | Urs Christen


The invention relates to the use of combination therapy of T1D with two drugs each specifically targeted to a different mechanism. Treatment with anti-CD3 monoclonal antibodies (MAbs) is given together with a MAb targeted to a chemokine protein that selectively directs the migration of lymphocytes to sites of inflammation or injury.

Drug Repurposing for Multiple Sclerosis

© Fraunhofer IME | Irmgard Tegder

The invention relates to the use of a drug (TMP-001), marketed for many years for another indication, in the treatment of MS. It has been tested extensively, though without significant success, in Alzheimer’s disease patients in which safety of high doses was comparable to placebo. Surprisingly, animal studies reveal a novel spectrum of activity in models of MS. The major advantages of this asset are the extensive clinical experience with the drug, its excellent oral safety profile and novel efficacy spectrum. TMP-001 offers a relatively straightforward development pathway to a novel oral therapy for MS.

 

 

Biofeedback Controlled Analgesia

© MEV

The invention comprises a new opioid infusion device that combines several advantages of TCI and PCA while avoiding certain disadvantages of the respective methods. Feedback controlled analgesia allows patients to titrate themselves with opioids until they reach adequate analgesia. The patented method allows control and maintenance of adequate and safe opioid analgesia without continuous adjustment by the patient or constant supervision by medical personal.

Inhibitors for NOX-4 for the Treatment of Neuropathic Pain

© Fraunhofer IME | Achim Schmidtko

The present invention relates to the use of the enzyme Nox4 as a target for the prevention and treatment of neuropathic pain. Accordingly, the use of Nox4 inhibitors is proposed, which reduce the activity and / or expression of Nox4. Mice deficient in Nox4 demonstrate considerably reduced pain-related behavior in animal models of neuropathic pain. Moreover, demyelination of peripheral nerves that typically occurs after nerve injury (SNI) is reduced in Nox4-deficient mice.

Detection of Sphingosine-1-Phosphate Receptor Agonists for Treatment of Neuropathic Pain

© Fraunhofer IME | Klaus Scholich

Sphingosine-1-phosphate (S1P) is an intracellular mediator with a wide spectrum of signaling functions. In neurons, its effects depend on the neuronal sub-type. Peripherally, S1P promotes neuronal growth and excitability and S1P receptor inhibition reduces inflammatory or chemotherapeutic pain. The present invention is a screening method for activators of the S1P receptor, including FTY720, which downregulate sensitization of nociceptive neurons in the spinal cord and therefore, offer a novel approach to the relief of traumatic or pain.


Receptor Agonists as Analgesics

© Fraunhofer IME | Sebastian Zinn, Michael Parnham

Many lipid mediators of inflammation act on multiple receptors to stimulate inflammatory cells. One of these mediators also acts at low affinity at receptors that are highly expressed in ganglion cells in the spinal cord. The invention relates to the finding that agonists at the low affinity lipid receptor downregulate sensitization of nociceptive neurons in the spinal cord and therefore, offer a novel approach to the relief of pain.

Novel Inhibitors for the Treatment of Chemotherapy-Induced Neuropathic Pain

© Fraunhofer IME | Marco Sisignano

Research findings have shown that cytotoxic drug therapy induces a specific cytochrome protein which produces large amounts of a mediator that sensitizes specific ion channels in nociceptive neu­rons. The inventive method involves the use of drugs which inhibit the function of the overexpressed protein and thus reduce the chemotherapy-induced sensitization of the neuronal ion channels. This action opens up a new approach to therapy of neuropathic pain and treatment options are limited.

Recombinant B7-H1 Fusion Protein as a Therapy Concept for Multiple Organ Failure in Sepsis

© Fraunhofer IME | Andreas von Knethen

The invention relates to a fusion protein of the extracellular part of an immunoinhibitory receptor and human immunoglobulin to be used for therapy of sepsis. The inhibitory receptor binds to a ligand on Tc cells and the specificity of the fusion protein can be enhanced by incorporating a binding peptide selective for Tc cells. The major advantage of this fusion protein is that it replaces inhibitory B7-H1 (PD-L1) molecules on organs lost during sepsis and induces prolonged tolerance rather than just inhibition of Tc cells. The therapeutic protein thus offers more than just acute inhibition of inflammation.

Antagonist of the Nuclear Hormone Receptor PPARγ for Sepsis Therapy

© Fraunhofer IME | Thales Kronenberger | Tilo Knape

The present invention pertains to a new compound and its derivatives. The compounds are selective, competitive peroxisome proliferator-activated receptor gamma (PPARγ) antagonists indicated for the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock. The advantage of PPARγ ant­agonism is the inhibition of T cell apoptosis and the prevention of “immune paralysis”. The compounds, in con­trast to available agents, are competitive inhibitors, thus facilitating control of paren­teral dosing. The new compounds permit careful timing of sepsis therapy to target hypo- rather than hyper-inflammation during sepsis.

Recombinant Human Cytokine Therapy for Chronic Inflammatory Diseases

© Fraunhofer IME / Andreas Weigert

The discovery of an N-modified interleukin (N-mod IL-X) as an endogenous antagonist of several pro-inflammatory cytokine recep­tors opens up a new approach to therapy of chronic inflammatory diseases. The invention comprises a recombinant form of N-mod IL-X which is suitable for therapeu­tic administration. Because of its antagonist action at multiple cytokine receptors, it represents a single drug candidate which targets various inflammatory processes with corresponding broad therapeutic activity.

Implant for Delayed Release of Therapeutic Biologicals

© Fraunhofer IME | Matthias Wacker

The invention relates to the use of a novel implant formulation, for subcutaneous insertion, which releases the protein drug slowly from the implant, but maintains the stability of the therapeutic protein drug. The implant formulation offers the possibility of regulating the bioavailability of biologicals, thereby reducing their toxicity and obviating the need for frequent injections.

Neutralizing Antibody for Immune Reactivation in Cancer

© Fraunhofer IME | Andreas von Kneten

The discovery of an interleukin that is produced in tumors and suppresses the anti-tumor activity of a number of immune cells opens up a new approach to the therapy of cancer. The invention comprises a neutralizing against said interleukin, which is suitable for therapeutic administration. Because of its activity in an experimental tumor model that is resistant to current immune checkpoint therapy (anti-PD-1), the target may be suitable for patients/entities that do not respond to immune checkpoint blockade and for use in combinatorial approaches.